Avoid common mistakes on your manuscript.
Correction to: Pharm Res (2016) 33:1899–1912
The correct version of Fig. 7 appears here. The image in Panel VI (earlier, “RAP-TRE”) has been replaced with the correct image. Sub-panels of have been re-labelled.
Histopathology of lung in animals that were: (1) Infected, untreated (II) Infected + treated with Inhalation – Rap particles: daily dosing (I-RAP 10 D) for 10 days (III) Infected + Inhalation – Rap particles: alternate day dosing (I-RAP 10 ALT) (IV) Infected + Inhalation-Rap particles: weekly dosing (I-RAP 10 WKLY) (V) Infected + Inhalation – Rap trehalose particles particles: daily dosing (I-RAP 10 TRE-D) (VI) Infected + Oral Isoniazid-Rifabutin (125 µg) + Inhalation-Isoniazid Rifabutin particles: daily dosing (O-INH-RFB + I-INH-RFB-D) (VII) Infected + Oral Isoniazid-Rifabutin (125 µg) + Inhalation – Isoniazid Rifabutin particles: daily dosing (O-INH-RFB + I-RAP-D) (VIII) Infected + Inhalation—Isoniazid-Rifabutin-Rap particles: daily dosing (I-INH + RFB + RAP-D) (IX) Infected + Inhalation – Blank PLGA particles: daily dosing (I-BLK-D)
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gupta, A., Sharma, D., Meena, J. et al. Correction to: Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. Pharm Res 39, 1027–1028 (2022). https://doi.org/10.1007/s11095-022-03258-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-022-03258-2